You are here: Industry Insights > Repatha

News List

Amgen receives NMPA approval for Repatha in China biospectrumasia
January 29, 2019
Repatha is an innovative biologic medicine proven to effectively lower LDL-C
Amgen's Repatha shows durable treatment effect in long-term study biospectrumasia
December 03, 2018
The results of all analyses were presented at the American Heart Association's Scientific Sessions 2018 in Chicago.
Amgen cuts price of cholesterol drug Repatha by 60% pharmaceutical-technology
October 29, 2018
Amgen has announced plans to reduce the price of its cholesterol drug Repatha by 60% to $5,850 per year, in an effort to improve affordability through lowering patient copays.
EU approves Repatha for reduction of CV risk pharmatimes
May 24, 2018
The drug can be used to reduce cardiovascular risk - by lowering low-density lipoprotein cholesterol (LDL-C) levels - as an adjunct to correction of other risk factors.
Amgen Receives EC Approval for Repatha americanpharmaceuticalreview
May 18, 2018
Amgen announced that the European Commission (EC) has approved a new indication in the Repatha (evolocumab) label for adults with established atherosclerotic cardiovascular disease
FDA Approves Repatha to Prevent Heart Attack, Stroke americanpharmaceuticalreview
December 06, 2017
The U.S. Food and Drug Administration (FDA) has approved Repatha (evolocumab) as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease.
Landmark outcomes study shows that Repatha decreases LDL-C to unprecedented low levels cphi-online
March 20, 2017
Amgen has announced that the 27,564-patient Repatha (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha.